PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: CUSTOMER LANDSCAPE PART 08: MARKET SEGMENTATION BY END-USER • Segmentation by end-user • Comparison by end-user • Pharmaceutical and biotechnology companies – Market size and forecast 2017-2022 • Healthcare centers – Market size and forecast 2017-2022 • Academic institutes and CROs – Market size and forecast 2017-2022 • Market opportunity by end-user PART 09: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Technological advancements • Increase in personalized medicine • Increasing number of CROs PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Agilent Technologies • BD • BioMerieux • Merck KGaA • Roche • Siemens • Thermo Fisher Scientific PART 15: APPENDIX • List of abbreviations     Exhibit 01: Parent market Exhibit 02: Global molecular diagnostics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global multiplexed diagnostics market – Market size and forecast 2017-2022 ($ bn) Exhibit 09: Global multiplexed diagnostics market – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Customer landscape Exhibit 19: End-user – Market share 2017-2022 (%) Exhibit 20: Comparison by end-user Exhibit 21: Pharmaceutical and biotechnology companies – Market size and forecast 2017-2022 ($ bn) Exhibit 22: Pharmaceutical and biotechnology companies – Year-over-year growth 2018-2022 (%) Exhibit 23: Healthcare centers – Market size and forecast 2017-2022 ($ bn) Exhibit 24: Healthcare centers – Year-over-year growth 2018-2022 (%) Exhibit 25: Academic institutes and CROs – Market size and forecast 2017-2022 ($ bn) Exhibit 26: Academic institutes and CROs – Year-over-year growth 2018-2022 (%) Exhibit 27: Market opportunity by end-user Exhibit 28: Global multiplexed diagnostics market – Market share by geography 2017-2022 (%) Exhibit 29: Regional comparison Exhibit 30: Americas – Market size and forecast 2017-2022 ($ bn) Exhibit 31: Americas – Year-over-year growth 2018-2022 (%) Exhibit 32: Top 3 countries in Americas Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ bn) Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 35: Top 3 countries in EMEA Exhibit 36: APAC – Market size and forecast 2017-2022 ($ bn) Exhibit 37: APAC – Year-over-year growth 2018-2022 (%) Exhibit 38: Top 3 countries in APAC Exhibit 39: Market opportunity Exhibit 40: Vendor landscape Exhibit 41: Landscape disruption Exhibit 42: Vendors covered Exhibit 43: Vendor classification Exhibit 44: Market positioning of vendors Exhibit 45: Agilent Technologies overview Exhibit 46: Agilent Technologies – Business segments Exhibit 47: Agilent Technologies – Organizational developments Exhibit 48: Agilent Technologies – Geographic focus Exhibit 49: Agilent Technologies– Segment focus Exhibit 50: Agilent Technologies – Key offerings Exhibit 51: BD overview Exhibit 52: BD – Business segments Exhibit 53: BD – Organizational developments Exhibit 54: BD – Geographic focus Exhibit 55: BD – Segment focus Exhibit 56: BD – Key offerings Exhibit 57: BioMerieux overview Exhibit 58: BioMerieux – Business segments Exhibit 59: BioMerieux – Organizational developments Exhibit 60: BioMerieux – Geographic focus Exhibit 61: BioMerieux – Segment focus Exhibit 62: BioMerieux – Key offerings Exhibit 63: Merck KGaA overview Exhibit 64: Merck KGaA – Business segments Exhibit 65: Merck KGaA – Organizational developments Exhibit 66: Merck KGaA – Geographic focus Exhibit 67: Merck KGaA – Segment focus Exhibit 68: Merck KGaA – Key offerings Exhibit 69: Roche overview Exhibit 70: Roche – Business segments Exhibit 71: Roche – Organizational developments Exhibit 72: Roche – Geographic focus Exhibit 73: Roche – Segment focus Exhibit 74: Roche – Key offerings Exhibit 75: Siemens overview Exhibit 76: Siemens – Business segments Exhibit 77: Siemens – Organizational developments Exhibit 78: Siemens – Geographic focus Exhibit 79: Siemens – Segment focus Exhibit 80: Siemens – Key offerings Exhibit 81: Thermo Fisher Scientific overview Exhibit 82: Thermo Fisher Scientific – Business segments Exhibit 83: Thermo Fisher Scientific – Organizational developments Exhibit 84: Thermo Fisher Scientific – Geographic focus Exhibit 85: Thermo Fisher Scientific – Segment focus Exhibit 86: Thermo Fisher Scientific – Key offerings

Agilent Technologies BD BioMerieux Merck KGaA Roche Siemens Thermo Fisher Scientific